Corcept Therapeutics Incorporated (CORT)
NASDAQ · Healthcare · Biotechnology
Corcept Therapeutics Incorporated is a Healthcare company with a market capitalization of $11.58B and a trailing P/E ratio of 238.1.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | April 30, 2026 | $-0.30 | $-0.14 | -114.3% |
| Q4 2025 | February 24, 2026 | $0.20 | $0.25 | -21.3% |
| Q3 2025 | November 4, 2025 | $0.16 | $0.14 | +14.3% |
| Q2 2025 | July 31, 2025 | $0.29 | $0.19 | +52.6% |
| Q1 2025 | May 5, 2025 | $0.17 | $0.14 | +21.4% |
| Q4 2024 | February 26, 2025 | $0.26 | $0.42 | -38.6% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 9,442,750 | 9.04% | 8.7 | +9.3% |
| June 30, 2026 | 8,641,452 | 8.27% | 8.4 | +0.8% |
| June 15, 2026 | 8,569,293 | 8.21% | 8.8 | -2.5% |
| May 29, 2026 | 8,793,063 | 8.42% | 8.6 | -5.6% |
| May 15, 2026 | 9,315,811 | 8.92% | 6.3 | -13.0% |
| April 30, 2026 | 10,710,814 | 10.26% | 11.5 | -5.6% |
| April 15, 2026 | 11,342,506 | 9.46% | 9.7 | -8.9% |
| March 31, 2026 | 12,449,551 | 10.39% | 5.0 | -4.4% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Corcept Therapeutics Incorporated's market cap?
As of August 13, 2026, Corcept Therapeutics Incorporated (CORT) has a market capitalization of $11.58B.
What is Corcept Therapeutics Incorporated's P/E ratio?
Corcept Therapeutics Incorporated trades at a trailing price-to-earnings (P/E) ratio of 238.1. Its forward P/E is 54.4.
Does Corcept Therapeutics Incorporated pay a dividend?
Corcept Therapeutics Incorporated does not currently pay a dividend.
What sector is CORT in?
Corcept Therapeutics Incorporated is in the Healthcare sector, specifically the Biotechnology industry.
What is Corcept Therapeutics Incorporated's short interest?
As of the July 15, 2026 FINRA settlement, 9,442,750 CORT shares were sold short, or 9.04% of shares outstanding. Days to cover: 8.7. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Corcept Therapeutics Incorporated's revenue?
In its latest reported fiscal year (ending December 31, 2025), Corcept Therapeutics Incorporated reported revenue of $761.41M and net income of $99.65M.
Ask your own questions about CORT
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.